News
See what has been written about us in the press as well as news of our developments. If you would like further information on the company, our people and innovations,
please contact us.
2011-12-01
The ORCHID alliance brings together TB expertise of institutions from academia, government research centres, not-for-profit organizations and biotechs. The European Union’s Seventh Framework Programme funds the project they are working on.
Within Orchid, Nanologica’s first goal is to deal with the immediate formulation problems associated with the poor water solubility of GSK’s and other partner members’ TB compounds.
“Nanologica’s carrier materials are useful in the pharmaceutical industry. It can improve the formulation and solubility of water-insoluble active pharmaceutical compounds, to control their pharmacokinetic parameters (such as bioavailability). With this, we can achieve specific targeted release of active compounds”, Krim Talia, CEO Nanologica
After years of extensive research in the area of pharmaceutical excipients, Nanologica has shown the value of their silica-based porous materials. Through slow and controlled release from the porous particles, the materials enhance significantly the solubility of pharmaceutical compounds.
Nanologica’s research team and other leading scientists worldwide will pull their expertise to investigate the potential of three different areas of research, all of which have shown potential effect against TB.
The three areas to be investigated are:
β-lactams – new evidence suggests that a novel approach could make these broad-spectrum antibiotics effective against TB. This approach will seek to design new animal models to demonstrate the potential of B-lactams as treatments against TB.
New InhA inhibitors – GSK, in collaboration with TB Alliance, has recently identified a chemical series that can inhibit recognised known TB target (InhA), which is essential for the bacterium’s survival. Tool compounds in this series have shown active against multi drug resistant strains (MDR-TB) in the lab and have also demonstrated promising activity in animal models of Mycobacterium tuberculosis.
Whole-cell hits – Compounds that have been shown to be active against TB in High Throughput Screening but their mode of action is unknown. The project will aim to understand this activity.
The €10M project is part of the Seventh Framework Programme for Research and Technological Development (FP7), led and part funded by the European Union which is providing €5.4M. The remainder of the funds will come from the ORCHID partners, largely from the provision of expertise and resources.
About ORCHID
The 11 partners that make up ORCHID are:
• The University of Birmingham – Birmingham, UK
• Univerza v Ljubljani – Ljubljana, Slovenia
• Institut National de la Sante et de la Recherche Médicale (INSERM) – Toulouse, France
• Global Alliance for Tuberculosis Drug Development - New York, US
• Nanologica AB – Stockholm, Sweden
• Cellzome AG – Heidelberg. Germany
• Universite Pierre et Marie Curie – Paris, France
• Ecole Polytechnique Federale de Lausanne – Lausanne, Switzerland
• The Federal State Scientific Institution Saint-Petersburg Scientific Research Pasteur Institute of Epidemiology - Saint Petersburg, Russia
• Microbiology and Federal State Institution Saint Petersburg Research Institute of Phthisiopulmonology of the Federal Agency for High Technology Medical Aid - Saint Petersburg, Russia
• Institut Pasteur Korea – Bundang gu, Korea
• GSK Tres Cantos Medicines Development Campus- Madrid, Spain
Nanologica becomes a strategic partner in €10M EU project to develop new treatments for tuberculosis
Nanologica leverages its carrier materials to play a key part in the four-year EU project, ORCHID. Led by GlaxoSmithKline (GSK), the €10 million project aims to discover and develop new medicines against multiple drug resistance tuberculosis (TB).The ORCHID alliance brings together TB expertise of institutions from academia, government research centres, not-for-profit organizations and biotechs. The European Union’s Seventh Framework Programme funds the project they are working on.
Within Orchid, Nanologica’s first goal is to deal with the immediate formulation problems associated with the poor water solubility of GSK’s and other partner members’ TB compounds.
“Nanologica’s carrier materials are useful in the pharmaceutical industry. It can improve the formulation and solubility of water-insoluble active pharmaceutical compounds, to control their pharmacokinetic parameters (such as bioavailability). With this, we can achieve specific targeted release of active compounds”, Krim Talia, CEO Nanologica
After years of extensive research in the area of pharmaceutical excipients, Nanologica has shown the value of their silica-based porous materials. Through slow and controlled release from the porous particles, the materials enhance significantly the solubility of pharmaceutical compounds.
Nanologica’s research team and other leading scientists worldwide will pull their expertise to investigate the potential of three different areas of research, all of which have shown potential effect against TB.
The three areas to be investigated are:
β-lactams – new evidence suggests that a novel approach could make these broad-spectrum antibiotics effective against TB. This approach will seek to design new animal models to demonstrate the potential of B-lactams as treatments against TB.
New InhA inhibitors – GSK, in collaboration with TB Alliance, has recently identified a chemical series that can inhibit recognised known TB target (InhA), which is essential for the bacterium’s survival. Tool compounds in this series have shown active against multi drug resistant strains (MDR-TB) in the lab and have also demonstrated promising activity in animal models of Mycobacterium tuberculosis.
Whole-cell hits – Compounds that have been shown to be active against TB in High Throughput Screening but their mode of action is unknown. The project will aim to understand this activity.
The €10M project is part of the Seventh Framework Programme for Research and Technological Development (FP7), led and part funded by the European Union which is providing €5.4M. The remainder of the funds will come from the ORCHID partners, largely from the provision of expertise and resources.
About ORCHID
The 11 partners that make up ORCHID are:
• The University of Birmingham – Birmingham, UK
• Univerza v Ljubljani – Ljubljana, Slovenia
• Institut National de la Sante et de la Recherche Médicale (INSERM) – Toulouse, France
• Global Alliance for Tuberculosis Drug Development - New York, US
• Nanologica AB – Stockholm, Sweden
• Cellzome AG – Heidelberg. Germany
• Universite Pierre et Marie Curie – Paris, France
• Ecole Polytechnique Federale de Lausanne – Lausanne, Switzerland
• The Federal State Scientific Institution Saint-Petersburg Scientific Research Pasteur Institute of Epidemiology - Saint Petersburg, Russia
• Microbiology and Federal State Institution Saint Petersburg Research Institute of Phthisiopulmonology of the Federal Agency for High Technology Medical Aid - Saint Petersburg, Russia
• Institut Pasteur Korea – Bundang gu, Korea
• GSK Tres Cantos Medicines Development Campus- Madrid, Spain
2011-10-27
”Andreas strong commercial background puts him in good stead to lead Nanologica in its next lifecycle phase. With the market sectors identified, Andreas is focused on streamlining exclusive long-term partnerships with big pharmaceutical and cosmetic companies. This strategy can help push customized products into niche markets,” says Krim Talia.
Andreas is currently working on challenges within his field of expertise, as he has extensive experience in business intelligence and had even started his own consultancy company, Wide Narrow.
”I am excited to join Nanologicas devoted and brilliant team. Together I am convinced that we can transform our excellence in research to a commercial success. I am thrilled to be the one leading Nanologica when we introduce our new line of drug delivery platforms such as the Atazanavir booster. Its potential in enhancing biovailability is invaluable in developing products for various applications.”
Nanologica AB announces new CEO
Nanologica AB names Andreas Bhagwani to replace Krim Talia as CEO. The founding partner announced he is stepping down from the company and has secured the addition of Andreas, an MBA graduate from the Stockholm School of Economics.”Andreas strong commercial background puts him in good stead to lead Nanologica in its next lifecycle phase. With the market sectors identified, Andreas is focused on streamlining exclusive long-term partnerships with big pharmaceutical and cosmetic companies. This strategy can help push customized products into niche markets,” says Krim Talia.
Andreas is currently working on challenges within his field of expertise, as he has extensive experience in business intelligence and had even started his own consultancy company, Wide Narrow.
”I am excited to join Nanologicas devoted and brilliant team. Together I am convinced that we can transform our excellence in research to a commercial success. I am thrilled to be the one leading Nanologica when we introduce our new line of drug delivery platforms such as the Atazanavir booster. Its potential in enhancing biovailability is invaluable in developing products for various applications.”
2011-03-21
www.swedenbio.se/en/Registrations/Life-Science-Investment-Day/Life-Science-Investment-Day-Scandin...
Nanologica presents at Life Science Investment Day 2011
A team from Nanologica attended SwedenBio's Life Science Investment Day 2011 on March 21st to give a presentation about their latest developments in the field of drug delivery and their daughter company NLAB Bioscience. The event was attended by some of the leading companies in drug development and the the largest life science investment firms in Europe. To read more about the event and the participants:www.swedenbio.se/en/Registrations/Life-Science-Investment-Day/Life-Science-Investment-Day-Scandin...
2011-02-22
Nanologicas daughter company NLAB Bioscience will be attending IMAGINENANO April 11-14, Bilbao, Spain
IMAGINENANO2011, the largest International Event on Nanoscience and Nanotechnology (April 11-14, 2011), to be held in Spain [Bilbao Exhibition Centre]. NLAB Bioscience will be present at the NanoBio&Med Conference, where the most recent international developments in the field of Nanobiotechnology and Nanomedicine will be presented. www.imaginenano.com/2011-01-17
Currently NLAB Materials offers a range of nanoporous materials (developed by Nanologica AB) with various morphologies, particle and pore sizes, functional groups and compositions.
NLAB Materials aims to establish a platform for researchers from both – the industry and academia - to gain access to the latest technological breakthroughs in the field of nanostructured materials from around the world.
For the industry, this platform will be the one stop shop to browse, compare and order materials most suitable for their application.
Through this platform, researchers will be able to market their technology to their target customers. For more inquiries about the commercialization opportunities contact us at arnav@nlabmaterials.com
Nanologica launches NLAB Materials: Online Store for Nanoporous Materials!
Nanologica AB has recently launched NLAB Materials (www.nlabmaterials.com),an online store for the commercialization of nanostructured technology.Currently NLAB Materials offers a range of nanoporous materials (developed by Nanologica AB) with various morphologies, particle and pore sizes, functional groups and compositions.
NLAB Materials aims to establish a platform for researchers from both – the industry and academia - to gain access to the latest technological breakthroughs in the field of nanostructured materials from around the world.
For the industry, this platform will be the one stop shop to browse, compare and order materials most suitable for their application.
Through this platform, researchers will be able to market their technology to their target customers. For more inquiries about the commercialization opportunities contact us at arnav@nlabmaterials.com